AbbVie surprises Street with solid earnings, priority FDA review for endometriosis med
admin 27th October 2017 Uncategorised 0Looming generic competition for AbbVie’s top-selling drug, Humira, threatens the top line while putting extreme pressure on the company to deliver follow-up blockbusters from its pipeline. Today the company took a big step toward putting investors’ minds at ease on both counts, with better-than-expected third-quarter results.
More: AbbVie surprises Street with solid earnings, priority FDA review for endometriosis med
Source: fierce